[go: up one dir, main page]

MX2010004660A - NUEVOS ANTICUERPOS ESPECIFICOS DE LOS PEPTIDOS ß-AMILOIDES Y SUS USOS COMO AGENTES DE DIAGNOSTICO Y DROGAS. - Google Patents

NUEVOS ANTICUERPOS ESPECIFICOS DE LOS PEPTIDOS ß-AMILOIDES Y SUS USOS COMO AGENTES DE DIAGNOSTICO Y DROGAS.

Info

Publication number
MX2010004660A
MX2010004660A MX2010004660A MX2010004660A MX2010004660A MX 2010004660 A MX2010004660 A MX 2010004660A MX 2010004660 A MX2010004660 A MX 2010004660A MX 2010004660 A MX2010004660 A MX 2010004660A MX 2010004660 A MX2010004660 A MX 2010004660A
Authority
MX
Mexico
Prior art keywords
drugs
beta
antibodies specific
diagnostic agents
amyloid peptides
Prior art date
Application number
MX2010004660A
Other languages
English (en)
Inventor
Laurent Pradier
Veronique Blanchard-Bregeon
Eugeen Vanmechelen
Pierre Grognet
Nicolas Sergeant
Marie Gompel
Andre Delacourte
Luc Buee
Original Assignee
Inserm Inst Nat De La Sante De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38925731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010004660(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inserm Inst Nat De La Sante De filed Critical Inserm Inst Nat De La Sante De
Publication of MX2010004660A publication Critical patent/MX2010004660A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un anticuerpo monoclonal que se une específicamente a la región N-terminal de péptidos Aß8-x, estando x comprendiendo desde 11 a 42, y que no reconoce ni Aß1-40, ni Aß1-42 y que presenta una elevada afinidad con respecto a péptidos Aß8-x, tal como se determina mediante la formación de complejo inmunológico entre el anticuerpo monoclonal y el péptico Aß8-x.
MX2010004660A 2007-10-29 2008-10-24 NUEVOS ANTICUERPOS ESPECIFICOS DE LOS PEPTIDOS ß-AMILOIDES Y SUS USOS COMO AGENTES DE DIAGNOSTICO Y DROGAS. MX2010004660A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07119537 2007-10-29
PCT/EP2008/064432 WO2009056490A1 (en) 2007-10-29 2008-10-24 NEW ANTIBODIES SPECIFIC OF THE β-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS

Publications (1)

Publication Number Publication Date
MX2010004660A true MX2010004660A (es) 2010-07-30

Family

ID=38925731

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004660A MX2010004660A (es) 2007-10-29 2008-10-24 NUEVOS ANTICUERPOS ESPECIFICOS DE LOS PEPTIDOS ß-AMILOIDES Y SUS USOS COMO AGENTES DE DIAGNOSTICO Y DROGAS.

Country Status (27)

Country Link
US (1) US8343493B2 (es)
EP (1) EP2205633A1 (es)
JP (1) JP5421277B2 (es)
KR (1) KR20100097651A (es)
CN (1) CN101883792B (es)
AP (1) AP2957A (es)
AR (1) AR069085A1 (es)
AU (1) AU2008317705B2 (es)
CA (1) CA2703825A1 (es)
CL (1) CL2008003197A1 (es)
CO (1) CO6270369A2 (es)
CR (1) CR11396A (es)
EA (1) EA201070539A1 (es)
EC (1) ECSP10010142A (es)
HN (1) HN2010000880A (es)
IL (1) IL205398A0 (es)
MA (1) MA31793B1 (es)
MX (1) MX2010004660A (es)
MY (1) MY155144A (es)
NI (1) NI201000075A (es)
NZ (1) NZ585000A (es)
TN (1) TN2010000197A1 (es)
TW (1) TW200936605A (es)
UA (1) UA103602C2 (es)
UY (1) UY31433A1 (es)
WO (1) WO2009056490A1 (es)
ZA (1) ZA201002989B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2439490T3 (es) * 2007-01-05 2014-01-23 University Of Zurich Anticuerpo anti-beta amiloide y usos del mismo
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
WO2010069603A1 (en) 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
SG183369A1 (en) 2010-03-03 2012-09-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
EP2511296A1 (en) * 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
CN103796679B (zh) 2011-06-23 2016-10-19 比奥根国际神经科学公司 抗-α突触核蛋白结合分子
WO2013167681A1 (en) 2012-05-10 2013-11-14 Georg-August-Universität Göttingen CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST Αβ OLIGOMERS
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP3374381A4 (en) * 2015-11-09 2019-05-15 The University Of British Columbia EPITOPES IN THE AMYLOID-BETA MEDIUM REGION AND CONFORMITY-SELECTIVE ANTIBODIES THEREOF
CN116333108A (zh) 2016-07-18 2023-06-27 英属哥伦比亚大学 淀粉样蛋白β的抗体
WO2018017754A1 (en) 2016-07-19 2018-01-25 Duke University Therapeutic applications of cpf1-based genome editing
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
CA3073066A1 (en) 2017-08-22 2019-02-28 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
EP3861023A1 (en) 2018-10-04 2021-08-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Humanised anti-n-truncated amyloid beta monoclonal antibody
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
WO2023111168A1 (en) * 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag A novel antibody for detection of amyloid beta 42 (aβ42)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006513259A (ja) * 2002-07-24 2006-04-20 イノジェネティックス・ナムローゼ・フェンノートシャップ ベータ−アミロイド生成および／または凝集に関連した疾病の防止、処置および診断
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung

Also Published As

Publication number Publication date
CR11396A (es) 2012-10-18
MY155144A (en) 2015-09-15
CL2008003197A1 (es) 2010-01-15
AU2008317705A1 (en) 2009-05-07
HN2010000880A (es) 2014-03-10
US20110059092A1 (en) 2011-03-10
ZA201002989B (en) 2011-07-27
EA201070539A1 (ru) 2010-10-29
CN101883792A (zh) 2010-11-10
WO2009056490A1 (en) 2009-05-07
ECSP10010142A (es) 2010-07-30
AP2957A (en) 2014-08-31
UY31433A1 (es) 2009-05-29
NZ585000A (en) 2012-08-31
CN101883792B (zh) 2014-08-27
TW200936605A (en) 2009-09-01
AR069085A1 (es) 2009-12-30
EP2205633A1 (en) 2010-07-14
UA103602C2 (ru) 2013-11-11
NI201000075A (es) 2010-09-23
IL205398A0 (en) 2010-12-30
CA2703825A1 (en) 2009-05-07
JP5421277B2 (ja) 2014-02-19
CO6270369A2 (es) 2011-04-20
AP2010005249A0 (en) 2010-06-30
KR20100097651A (ko) 2010-09-03
JP2011502139A (ja) 2011-01-20
MA31793B1 (fr) 2010-10-01
AU2008317705B2 (en) 2014-06-05
TN2010000197A1 (en) 2011-11-11
US8343493B2 (en) 2013-01-01

Similar Documents

Publication Publication Date Title
MX2010004660A (es) NUEVOS ANTICUERPOS ESPECIFICOS DE LOS PEPTIDOS ß-AMILOIDES Y SUS USOS COMO AGENTES DE DIAGNOSTICO Y DROGAS.
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
UA98983C2 (uk) Антитіло проти гепсидину та його застосування
WO2020146902A3 (en) Anti-variable muc1* antibodies and uses thereof
NZ724904A (en) Hybrid immunoglobulin containing non-peptidyl linkage
WO2007133623A3 (en) Peptide diagnostic agent for lyme disease
CY1118709T1 (el) Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf
NZ602256A (en) Monoclonal antibodies against the rgm a protein and uses thereof
EP2535351A3 (en) Dual specificity antibody fusions
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
EP4345111A3 (en) High affinity human antibodies to human il-4 receptor
NZ701444A (en) Antibodies to matrix metalloproteinase 9
WO2007117577A3 (en) High affinity human antibodies to human il-18 receptor
WO2006094192A3 (en) Humanized l243 antibodies
WO2008098917A3 (en) Novel antibodies against igf-ir
NZ615441A (en) Humanised antibodies to toll-like receptor 2 and uses thereof
MX340772B (es) Medios y metodos para fabricar neurotoxina altamente pura.
NZ583894A (en) Antibodies that bind to a non atp binding p2x7 receptor
NZ595863A (en) Antibodies to egfl7 and methods for their use
MX2010001237A (es) Nuevos anticuerpos.
MX346560B (es) Anticuerpos anti-xcr1 humano.
WO2010011952A3 (en) Flip death effector domain derived peptides for inducing autophagy
IN2013MN00513A (es)
IN2014DN07875A (es)
MX2009008754A (es) Anticuerpos novedosos contra igf-1r.

Legal Events

Date Code Title Description
FG Grant or registration